Alnylam Surges on Historic $1B Revenue Milestone and Massive Earnings Beat
Alnylam Pharmaceuticals (ALNY) shares are sharply outperforming the broad market Thursday after the biotech giant reported first-quarter earnings that nearly doubled analyst expectations. The move is fueled by a historic milestone, as the company surpassed $1 billion in quarterly product revenues for the first time, driven by explosive demand for its flagship amyloidosis treatment.
Earnings Crush Wall Street Estimates
Alnylam Pharmaceuticals (ALNY) is the standout performer in the biotechnology sector today, with shares climbing 4.40% to $314.45. This move represents a massive divergence from the broader market, as the S&P 500 (SPY) remains nearly flat with a modest 0.29% gain. The primary catalyst is a dominant first-quarter earnings report that saw the company deliver non-GAAP earnings per share (EPS) of $1.99, obliterating the consensus estimate of $0.91.
Total revenue for the quarter reached $1.17 billion, a 96% increase year-over-year, surpassing the $1.12 billion forecasted by analysts. The company’s transition to profitability was a key highlight for investors, as Alnylam reported a GAAP net income of $206 million compared to a net loss in the same period last year.
A Historic $1 Billion Milestone
The most significant takeaway from the report was the achievement of a long-held strategic goal: crossing the $1 billion threshold in quarterly net product revenues. CEO Yvonne Greenstreet, M.D., characterized the quarter as a "strong start" and a "significant financial milestone" for the company.
This growth was almost entirely spearheaded by the TTR franchise, which generated $910 million in revenue, representing a staggering 153% increase compared to the first quarter of 2025. The primary engine of this growth is AMVUTTRA, which has seen rapid adoption for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) following its successful U.S. launch and subsequent global rollouts.
Operational Leverage and Pipeline Progress
Beyond the headline numbers, Alnylam demonstrated significant improving operating leverage. The company's non-GAAP operating margin expanded to 29%, up from 13% a year ago, even as it continued to fund a deep research and development pipeline.
Investors are also reacting positively to the company's progress in its next-generation therapies. Alnylam recently initiated a Phase 1 study for ALN-2232, its first adipose-targeted program aimed at obesity and weight management. This move into the highly lucrative metabolic space, combined with ongoing Phase 3 trials for nucresiran and zilebesiran, provides a clear roadmap for growth beyond the current TTR franchise.
Forward Outlook and Market Context
Management reiterated its full-year 2026 financial guidance, projecting combined net product revenues between $4.9 billion and $5.3 billion. This consistency, paired with the massive Q1 beat, has eased concerns regarding valuation that had pressured the stock earlier in the year.
While the biotech sector has faced volatility due to shifting interest rate expectations, Alnylam’s fundamental execution is providing a strong idiosyncratic lift. With $3.0 billion in cash and marketable securities on the balance sheet, the company is well-positioned to reach its "Alnylam 2030" goals of global TTR leadership and sustained profitability.
Key Takeaways
- Alnylam reported Q1 non-GAAP EPS of $1.99, beating the $0.91 consensus by 118%.
- Achieved a historic milestone of $1.04 billion in quarterly product revenues, up 121% year-over-year.
- The TTR franchise, led by AMVUTTRA, saw 153% revenue growth to $910 million.
- Management reiterated full-year 2026 revenue guidance of $4.9 billion to $5.3 billion.